Perioperative Clinical Sales Specialist II — Remote Impact

Masimo; Omaha (NE); À distance; USD 85 000 - 120 000; Plein temps

Avantages offerts par ce poste

Remote work eligible

Comprehensive benefits

Résumé du poste

Masimo, a Danaher operating company, is seeking a Clinical Sales Specialist II for the Perioperative portfolio. Located in Omaha, NE, the role covers the region with remote work flexibility and requires clinical expertise to educate customers and drive implementations.

You will build relationships with key clinical customers, lead product evaluations, and support educational events. Travel up to 70-80% is expected with a strong focus on evidence-based outcomes.

Qualifications

• 5+ years of experience in a clinical setting.
• Experience within critical care.
• Strong critical care knowledge.
• Registered Respiratory Therapist or Registered Nurse (Preferred).
• Ability to use evidence and best practices to influence clinical outcomes.

Responsabilités

• Build and maintain relationships with key clinical customers across the Perioperative portfolio.
• Partner with sales to identify product evaluations, coach clinicians, and support conversions and in-servicing.
• Conduct clinical needs assessments and deliver recommendations aligned with standards and guidelines.
• Communicate insights and clinical developments to support marketing and sales effectiveness.
• Maintain expertise in hemodynamic monitoring and complete CRM and admin tasks.

Connaissances

Critical care knowledge

Evidence-based practice

Clinical education

Formation

Registered Respiratory Therapist or Registered Nurse

Description du poste

Masimo, a Danaher operating company, is seeking a Clinical Sales Specialist II for the Perioperative portfolio. Located in Omaha, NE, the role covers the region with remote work flexibility and requires clinical expertise to educate customers and drive implementations.

You will build relationships with key clinical customers, lead product evaluations, and support educational events. Travel up to 70-80% is expected with a strong focus on evidence-based outcomes.